DISCUSSION GUIDE

EndeavorRx®

The first and only FDA-authorized ADHD treatment delivered through a video game.

If your child is struggling with attention and focus, EndeavorRx may be a great addition to your child's current treatment plan. Since this is a new type of treatment, your healthcare professional may not be familiar with it. We put this guide together to help start a conversation and see if EndeavorRx is right for you and your child.

TIP: Print or download this guide and bring to your next appointment.

WHAT IS ENDEAVORRX?

- The EndeavorRx app is a digital treatment, delivered through a video game, and indicated for children ages 8-12 years old.
- EndeavorRx has been clinically proven to improve attention function as measured by computer-based testing in children with primarily inattentive and combined-type ADHD who have a demonstrated attention issue.
- EndeavorRx is an FDA-authorized medical device and must be prescribed by a healthcare professional as part of a therapeutic program.
- EndeavorRx is available on most iOS and Android™ devices.

HOW DOES IT WORK?

- The EndeavorRx treatment is delivered through an immersive and challenging video game experience.
- EndeavorRx works specifically by using sensory stimuli and simultaneous motor challenges designed to target the area of the brain that plays a key role in attention function.

- As a child progresses in the video game, the technology is continuously measuring their performance by using adaptive algorithms to adjust the difficulty and personalize the treatment experience for each individual.

HOW WILL IT BE PRESCRIBED?

- EndeavorRx is available through our pharmacy partner, Phil. If your child's healthcare professional decides EndeavorRx is appropriate, they will send the prescription to Phil.
- A prescription for EndeavorRx provides an initial 3-months of access to the treatment.
- EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child's health care provider
- At the end of the 3-month access period, you should consult with your child's healthcare professional to determine if your child should continue treatment.

HOW SHOULD IT BE USED?

- EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of ADHD.

- EndeavorRx is not intended to be used as a stand-alone therapeutic and is not a substitution for your child's ADHD medication.

WHAT IS TREATMENT LIKE?

The EndeavorRx treatment might feel repetitive and challenging for some children, and it takes commitment from you and your child to see results. You should expect tough moments on the path to improving your child's attention, but making this part of your family's routine can help.

Full details about EndeavorRx, including clinical trial data and important indications, safety, and warning information, can be found in the Instructions for Use.

QUESTIONS?

If you or your healthcare professional have any questions or would like to know more about EndeavorRx, please don't hesitate to reach out to Phil pharmacy.

Caregivers: Call **855.977.0975** (Press 3) or visit **www.phil.us/contact**

Healthcare Professionals: Call **855.977.0975** (Press 2) or email **md-help@phil.us**

EndeavorRx: Indications, Safety and Cautions

The EndeavorRx app is a digital treatment indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD. Patients who engage with EndeavorRx may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered as part of a therapeutic program and is not a substitute for ADHD medication. The most common side effects observed in children in EndeavorRx clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were observed with its use.

EndeavorRx was granted market approval through FDA's DeNovo pathway and is now a cleared Class II medical device.